BCIQ Profiles

Company Profile ReportTarget Profile Report

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy
FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k) pathway and the agency’s

Read the full 385 word article

How to gain access

Continue reading with a
two-week free trial.